Study on the treatment of transscleral cyclophotocoagulation in primary acute angle-closure glaucoma

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050573

Enrollment

Unknown

Registered

2021-08-29

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary acute angle closure glaucoma

Interventions

Experimental group:transscleral cyclophotocoagulation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Monocular or binocular PAACG acute grand mal; 2. The intraocular pressure cannot be reduced to normal after 24 hours of local and systemic application of various intraocular pressure-lowering drugs, or the intraocular pressure is reduced to normal, but UBM shows ciliary body hypertrophy or pronation, ciliary process hypertrophy, central anterior chamber The depth is less than 1.8mm.

Exclusion criteria

Exclusion criteria: 1. Secondary angle-closure glaucoma; 2. The attacked eye has a history of intraocular surgery or laser treatment in the past; 3. Patients with severe cardiovascular system, respiratory system or other systemic diseases who cannot tolerate transscleral laser cyclophotocoagulation; 4. Those who refuse to sign the informed consent form.

Design outcomes

Primary

Measure	Time frame
vision;intraocular pressure;white to white distance;central anterior chamber depth;Corner opening distance 500;Trabecular iris angle;Maximum ciliary process thickness;Trabecular Ciliary Process Angle;Crystal dome;Anterior chamber volume;	—

Secondary

Measure	Time frame
eye axis;lens thickness;	—

Countries

China

Contacts

Public ContactYu Lei

Eye Hospital China Academy of Chinese Medical Sciences

jackyyulei@hotmail.com+86 13811447112

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026